Sunshine Biopharma Inc Earnings: Miss on EPS and Revenue

Sunshine Biopharma Inc (SBFM) reported disappointing first-quarter results on April 3, 2026, missing analyst expectations on both earnings per share and revenue. The biotechnology company posted a loss of $0.54 per share, significantly worse than the estimated loss of $0.28 per share.

The EPS miss represented a negative surprise of 96.08%, with actual losses nearly doubling analyst projections. The $0.54 per share loss compared unfavorably to the $0.28 consensus estimate, marking a substantial earnings shortfall for the quarter.

Revenue performance also fell short of expectations, with SBFM generating $8.57 million in quarterly revenue against analyst estimates of $10.20 million. This represented a revenue miss of 15.91%, with actual sales coming in $1.63 million below projections.

The dual miss on both EPS and revenue metrics highlights operational challenges facing the company during the reporting period. The $8.57 million in revenue reflected weaker-than-anticipated business performance across the quarter.

This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.